Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
Azetukalner, a Novel, Potent Kv7 Channel Opener: Updates From the Ongoing Clinical Development Program in Major Depressive Disorder